Design Therapeutics, Inc.
DSGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.54 | -0.26 | -0.11 | -1.47 |
| FCF Yield | -2.60% | -7.58% | -7.70% | -2.82% |
| EV / EBITDA | -24.67 | -9.18 | -10.25 | -19.92 |
| Quality | ||||
| ROIC | -9.59% | -10.03% | -8.88% | -6.83% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.66 | 0.76 | 0.95 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 23.17% | 13.84% | -71.00% | -3.46% |
| Safety | ||||
| Net Debt / EBITDA | 0.79 | 0.94 | 0.57 | 1.22 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -11.80 | -599.80 | 0.00 | 0.00 |